gene

NCT

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about NCT: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

15Connections

30Hypotheses

0Analyses

11Outgoing

4Incoming

11Experiments

0Debates

Summary

NCT (Nicastrin) Gene

View on Wiki →

AI-generated illustration · click image to enlarge

Regenerate portrait ↻

🧬 Gene Info

Gene Symbol	NCT
Full Name	Nicastrin
Chromosome	1p31.3
Function	is an important component in the neurobiology of neurodegenerative diseases.
Pathways	circadian regulation
UniProt ID	Q92542
NCBI Gene ID	51594
Ensembl ID	ENSG00000103546
GeneCards	NCT
Human Protein Atlas	NCT
Associated Diseases	Alzheimer
Interactions	APH1, APP, PS1, PSEN, TAU, VCP
KG Connections	15 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: NCT — AlphaFold Q92542 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

FEEMSA Study: Laryngopharyngeal Function in Neurodegenerative Diseases (NCT04706234)

clinical · 4197 words

→

Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)

clinical · 4079 words

→

KarXT for Alzheimer's Disease Cognitive Impairment - MINDSET 2 (NCT06976203)

clinical · 3985 words

→

Pathway Diagram

graph TD
    NCT["NCT"]
    style NCT fill:#1a237e,stroke:#4fc3f7,stroke-width:3px,color:#fff
    circadian_regulation(["circadian regulation"])
    neurodegeneration["neurodegeneration"]

    NCT -->|"participates_in"| circadian_regulation
    NCT -->|"implicated_in"| neurodegeneration

    classDef gene fill:#1a3a2a,stroke:#4caf50,color:#e0e0e0
    classDef protein fill:#1a2a3a,stroke:#4fc3f7,color:#e0e0e0
    classDef disease fill:#3a1a1a,stroke:#ef5350,color:#e0e0e0
    classDef pathway fill:#2a1a3a,stroke:#ce93d8,color:#e0e0e0
    classDef mechanism fill:#2a2a1a,stroke:#ffd54f,color:#e0e0e0
    classDef drug fill:#1a2a2a,stroke:#80cbc4,color:#e0e0e0
    class circadian_regulation protein
    class neurodegeneration disease

Outgoing (11)

Target	Relation	Type	Str
Alzheimer	associated_with	disease	0.65
PS1	associated_with	gene	0.60
PS1	activates	gene	0.60
neurodegeneration	interacts_with	disease	0.60
VCP	interacts_with	gene	0.60
VCP	activates	gene	0.60
Alzheimer's disease	interacts_with	disease	0.60
ubiquitin-proteasome	participates_in	pathway	0.60
neurons	expressed_in	cell_type	0.60
PSEN	activates	gene	0.60
circadian regulation	participates_in	pathway	0.55

Incoming (4)

Source	Relation	Type	Str
APP	regulates	gene	0.60
APP	activates	gene	0.60
TAU	interacts_with	gene	0.60
APH1	activates	gene	0.60

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Closed-loop optogenetic targeting PV interneurons to restore	0.952	Alzheimer's disease	Circuit-level neural dynamics in neurode
Plasma NfL Elevation Secondary to BBB-Associated Transport D	0.940	-	What blood-brain barrier permeability ch
Glymphatic-Mediated Tau Clearance Dysfunction	0.865	neuroscience	Proteomics Differential Expression in AD
TREM2 R47H Variant-Driven Metabolic Dysfunction as the Prima	0.862	neurodegeneration	Variant Annotation and Prioritization of
TREM2-Mediated Microglial Dysfunction Disrupts Perivascular	0.861	neuroscience	TREM2 in Alzheimer's Disease: Mechanisms

Microglial-Mediated Tau Clearance Dysfunction via TREM2 Sign	0.827	neuroscience	Circuit-level neural dynamics in neurode
Targeting the Mechanistic Link Between AQP4 Dysfunction and	0.803	neurodegeneration	View
Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbate	0.785	-	Do β-amyloid plaques and neurofibrillary
Exosomal SNCA Propagation from Lysosome-Compromised Neurons	0.777	neurodegeneration	-
Selective blockade of classical-pathway activation downstrea	0.750	neurodegeneration	Does C1q function differ based on subcel
Tau dysfunction destabilizes labile pool	0.750	neurodegeneration	View
BACE1/NRG1 Axis Dysfunction Drives Excitatory/Inhibitory Imb	0.743	neurodegeneration	What are the physiological functions of
Microglial-Mediated Tau Clearance Dysfunction via TREM2 Rece	0.739	neuroscience	Circuit-level neural dynamics in neurode
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK	0.738	Alzheimer's Disease	Cell type vulnerability in Alzheimers Di
Matrix Metalloproteinase-9 and TIMP-1 Ratio in Peripheral Bl	0.735	-	What blood-brain barrier permeability ch
SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysoso	0.734	neurodegeneration	What molecular mechanisms link elevated
Metabolic-Support Secretome Dysfunction	0.730	neurodegeneration	Which specific factors in conditioned me
Calcium-Dependent S100B Release from Astrocyte End-Feet as a	0.725	-	What blood-brain barrier permeability ch
TBK1 Loss-of-Function Amplifies C1q-Mediated Synapse Elimina	0.724	neurodegeneration	How do the seven novel ALS genes functio
Astroglial Gap Junction Coordination via Connexin-43 Phospho	0.720	neurodegeneration	Perivascular spaces and glymphatic clear
SASP Secretome-based Molecular Distinction via CXCL1/CXCL2/M	0.720	neurodegeneration	How can senescent microglia be molecular
H4: Senomorphic Compounds Preserve Astrocyte Function While	0.710	neurodegeneration	Do APOE4-driven senescent astrocytes cau
Plasma Claudin-5 Proteolytic Fragments Distinguish Paracellu	0.705	-	What blood-brain barrier permeability ch
STMN2 Cryptic Exon Inclusion is the Earliest Loss-of-Functio	0.702	ALS	Causal Sequence of TDP-43 Nuclear Cleara
Lysosomal Acidification Failure: Convergent GBA1/LAMP2A–medi	0.700	neurodegeneration	-
Glucosylceramide Accumulation from GCase Deficiency Disrupts	0.700	neurodegeneration	-
VPS35 Retromer Dysfunction Creates a GCase Trafficking Bottl	0.700	neurodegeneration	-
TREM2 Agonism to Rescue APOE4-Induced Microglial Dysfunction	0.690	neurodegeneration	APOE4 targeting in neurodegeneration
CRISPR-Mediated Mitochondrial Genome Editing for Complex I D	0.681	neurodegeneration	CRISPR-based therapeutic approaches for
AQP4 Dysregulation Promotes Neuroinflammation Through Impair	0.680	neurodegeneration	What are the specific molecular mechanis

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (11)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Model	Status	Est. Cost
Tau depletion effects on neuronal development in primary cultures	exploratory		0.900	primary rodent neuronal cultur	proposed	N/A
Differential GWAS of schizophrenia vs PTSD	exploratory	schizophrenia, post-traumatic	0.900	human patients - European ance	proposed	N/A
Tau depletion effects on neuronal development in primary cultures	exploratory		0.900	primary rodent neuronal cultur	proposed	N/A
Creation and validation of 3xAD-ChAT-Cre mouse model	validation	Alzheimer's disease	0.900	3xAD-ChAT-Cre transgenic mice	proposed	N/A
NAD depletion effects on monocyte/macrophage differentiation	exploratory	Inflammatory bowel disease	0.900	Primary mouse and human monocy	proposed	N/A
FK866 treatment in DSS-induced colitis mouse model	validation	Inflammatory bowel disease (co	0.900	DSS-induced colitis mice	proposed	N/A
GTEx brain tissue expression analysis of MAPT/CRHR1 locus	exploratory	schizophrenia, post-traumatic	0.850	human brain tissue samples fro	proposed	N/A
FK866 in azoxymethane/DSS colitis-associated cancer model	validation	Colitis-associated cancer	0.850	AOM/DSS-treated mice	proposed	N/A
FK866 mechanism validation in Rag1-/- mice	validation	Inflammatory bowel disease	0.850	Rag1-/- mice with DSS-induced	proposed	N/A
Microtubule domain analysis in adult axons	exploratory		0.800	adult rodent axons	proposed	N/A
Tau depletion effects on microtubule domains in adult axons	exploratory		0.800	adult rodent neurons	proposed	N/A

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2- [PMID:31932797]	Zhou Y, Song WM, Andhey PS, Swain A, Lev	Nat Med	2020	1
Targeting Microglial Phagocytosis for Alzheimer's Disease Management: Natural, P [PMID:40641018]	Raghuvanshi S, Mazumder A, Das S	CNS & neurological disorders d	2026	0
ACSL4-mediated astrocyte ferroptosis augments neuroinflammation and exacerbates [PMID:41776085]	Wen H, Zi Y, Liu Z, Bai Y, Lin J et al.	Cell Death Differ	2026	0
Multimodal MR Imaging Reveals the Mechanisms of Post-Cardiac-Arrest Brain edema: [PMID:41933462]	Tan Y, Ye H, Ge Q, Wang P, Liu Z et al.	J Magn Reson Imaging	2026	0
Mapping the Brain's Glymphatic System. [PMID:41751308]	Voumvourakis K, Thomaidis NS, Tsiodras S	Biomedicines	2026	0
Aquaporin 4 knockdown alleviates traumatic brain edema and reduces neuronal axon [PMID:41967652]	Fang J, Pan X, Chen J	Neurobiol Dis	2026	0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025	0
The APOE-Microglia Axis in Alzheimer's Disease: Functional Divergence and Therap [PMID:40722268]	Unknown	Brain sciences	2025	0
Melatonin Mitigates Sleep Restriction-Induced Cognitive and Glymphatic Dysfuncti [PMID:40293704]	Sun H, Cao Q, He X, Du X, Jiang X, Wu T,	Molecular neurobiology	2025	0
Emerging Molecular Targets in Neurodegenerative Disorders: New Avenues for Thera [PMID:40922457]	["Eroglu E", "Harmanci N"]	Basic & clinical pharmacology	2025	0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025	0
Clearance mechanisms of the glymphatic/lymphatic system in the brain: new therap [PMID:41376656]	He Z, Sun J	Cognitive neurodynamics	2025	0
Glymphatic and meningeal lymphatic dysfunction in Alzheimer's disease: Mechanism [PMID:41152198]	Ding J, Zhao C, Hao X, Jiao H	Alzheimer's & dementia : the j	2025	0
When sleep fails, brain clearance suffers: the role of glymphatic impairment in [PMID:41315137]	["De la Herr\u00e1n-Arita Alberto K"]	Acta neurologica Belgica	2025	0
Soluble CSF1R promotes microglial activation and amyloid clearance in alzheimer' [PMID:41152873]	Zhang L, Chen K, Zeng R	J Neuroinflammation	2025	0
P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting [PMID:38513667]	Zhang D, Zhang W, Ming C, Gao X, Yuan H,	Neuron	2024	0
The necroptosis cell death pathway drives neurodegeneration in Alzheimer's disea [PMID:38852117]	Balusu S, De Strooper B	Acta neuropathologica	2024	0
The cornel Iridoid glycoside attenuated brain edema of the cerebral ischemia/rep [PMID:38950636]	Wang Z, Xue F, Zhang J	Fitoterapia	2024	0
Untangling the Role of TREM2 in Conjugation with Microglia in Neuronal Dysfuncti [PMID:36683512]	Basha SC, Ramaiah MJ, Kosagisharaf JR	J Alzheimers Dis	2023	0
Insulin Resistance and Diabetes Mellitus in Alzheimer's Disease. [PMID:34069890]	Burillo J, Marqués P, Jiménez B, Gonzále	Cells	2021	0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning NCT in their description or question text

Microglial-Mediated Tau Clearance Dysfunction via TREM2 Signaling

Score: 0.827 · neuroscience · 2026-04-07

## Mechanistic Overview Microglial-Mediated Tau Clearance Dysfunction via TREM2 Signaling starts from the claim that mod

Targeting the Mechanistic Link Between AQP4 Dysfunction and Ferroptosis Prevents

Score: 0.803 · neurodegeneration · 2026-04-17

## Mechanistic Overview Targeting the Mechanistic Link Between AQP4 Dysfunction and Ferroptosis Prevents Both Cytotoxic

Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbates Amyloid Pathology

Score: 0.785 · unknown disease · 2026-04-12

## Mechanistic Overview Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbates Amyloid Pathology starts from the

Selective blockade of classical-pathway activation downstream of C1q will reduce

Score: 0.750 · neurodegeneration · 2026-04-25

The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway

Tau dysfunction destabilizes labile pool

Score: 0.750 · neurodegeneration · 2026-04-25

Loss of tau function (as in disease states) selectively destabilizes the labile microtubule population, disrupting axona

BACE1/NRG1 Axis Dysfunction Drives Excitatory/Inhibitory Imbalance via PV Intern

Score: 0.743 · neurodegeneration · 2026-04-15

## Mechanistic Overview BACE1/NRG1 Axis Dysfunction Drives Excitatory/Inhibitory Imbalance via PV Interneuron Hypofuncti

Microglial-Mediated Tau Clearance Dysfunction via TREM2 Receptor Impairment

Score: 0.739 · neuroscience · 2026-04-12

**Molecular Mechanism and Rationale** The molecular foundation of this hypothesis centers on the disruption of the TREM

SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy D

Score: 0.738 · Alzheimer's Disease · 2026-04-02

## Mechanistic Overview SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction start

Matrix Metalloproteinase-9 and TIMP-1 Ratio in Peripheral Blood as an Early Indi

Score: 0.735 · unknown disease · 2026-04-26

Elevated MMP-9/TIMP-1 ratio reflects net proteolytic activity against the BBB, causing degradation of tight junction pro

SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysosomal Degradation via

Score: 0.734 · neurodegeneration · 2026-04-15

## Mechanistic Overview SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysosomal Degradation via Autophagosome-Ly

Metabolic-Support Secretome Dysfunction

Score: 0.730 · neurodegeneration · 2026-04-25

Healthy astrocytes provide a balanced fuel/redox/pH composition (including lactate, glucose, pyruvate, and NAD+/NADH-rel

Calcium-Dependent S100B Release from Astrocyte End-Feet as an Early Signal of As

Score: 0.725 · unknown disease · 2026-04-26

S100B is released from astrocytes upon inflammatory activation or metabolic stress, causing pericyte dysfunction and end

TBK1 Loss-of-Function Amplifies C1q-Mediated Synapse Elimination Through Type I

Score: 0.724 · neurodegeneration · 2026-04-13

**Molecular Mechanism and Rationale** The molecular cascade underlying TBK1 loss-of-function-mediated synapse eliminati

Astroglial Gap Junction Coordination via Connexin-43 Phosphorylation Modulation

Score: 0.720 · neurodegeneration · 2026-04-02

## Mechanistic Overview Astroglial Gap Junction Coordination via Connexin-43 Phosphorylation Modulation starts from the

NCT

Understanding Entity Pages

Summary

Wiki Pages (21)

Tolfenamic Acid PSP Trial (NCT04253132)

DIAN-TU-001 Trial (NCT01760005)

PMN310 Anti-Amyloid for AD (NCT06750432)

FEEMSA Study: Laryngopharyngeal Function in Neurodegenerative Diseases (NCT04706234)

Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)

KarXT for Alzheimer's Disease Cognitive Impairment - MINDSET 2 (NCT06976203)

Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT06223360)

Genistein for Mild Cognitive Impairment (NCT07385937)

Rotigotine and Rivastigmine Combination Therapy for Alzheimer's Disease (NCT06702124)

Portable Driving Simulator for PD Assessment (NCT03969927)

KarXT+EC Phase 3 (NCT07011732): Enhanced Formulation for AD Agitation

A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's D... (NCT06194799)

Vagal Nerve Stimulation for Parkinson's Disease (NCT07226284)

CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD

DBS Nucleus Basalis Trial (NCT07218081): Deep Brain Stimulation for AD

Cognitive Training to Reduce Incidence of Cognitive Impairment in Older Adults (NCT03848312)

ND0612 Subcutaneous Levodopa Infusion PD Trial (NCT04006210)

Tricaprilin Phase 3 ALTER-AD Study (NCT05809908)

Gait Pattern Analysis in Neurological Disease (NCT02994719)

Utilisation of Health Services and Quality of Life in Atypical Parkinsonian Syndromes (NCT06645626)

Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Admini... (NCT03899298)